Business Wire

IPA Announces Agreement to Acquire BioStrand BV – Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial ...

Acquisition includes wholly owned subsidiary businesses BioKey BV and BioClue BV. Platform is based on a proprietary biological discovery called HYFT™ patterns, signature sequences in DNA, RNA, and ...
Financial Post

BioStrand® Unveils a Revolutionary Approach to Biological Sequence Retrieval: A Fusion of Natural Language Processing and Database Research

VICTORIA, British Columbia — ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is thrilled to ...
Business Wire

IPA’s Subsidiary BioStrand Secures Second VLAIO Research Grant

DIEPENBEEK, Belgium--(BUSINESS WIRE)--Diepe IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) is pleased to share that IPA’s subsidiary Biostrand, a Belgian end-to ...
Financial Post

IPA Announces Agreement to Acquire BioStrand BV – Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial ...

New Platform Integrates Sequence Data and Information from Entire Biosphere Acquisition includes wholly owned subsidiary businesses BioKey BV and BioClue BV. Platform is based on a proprietary ...
The Globe and Mail

IPA Announces Agreement to Acquire BioStrand BV – Revolutionizing Biotherapeutics with Methodology to Encode Omics and Power Drug Development with Advanced Artificial ...

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA) (TSXV: IPA) is pleased to announce that it has entered into a definitive share purchase agreement (SPA) to acquire, through ...